T-TAS® WS Method Comparison

Eligibility Criteria

• * Males and females age 21 years or older.
• * Able and willing to provide written informed consent.
• * Hospitalization or doctor's visits within prior 30 days, except for routine checkup/physical examination.
• * Use of antiplatelet therapy within the past 7 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol.
• * Use of anticoagulant drugs within the past 7 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.
• * Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit COX-1 such as naproxen or ibuprofen within the past 3 days, unless confirmed to not inhibit platelet activity (such as celecoxib).
• * History of anemia.
• * Known thrombocytopenia (platelet count \< 100,000/μL).
• * Significant renal dysfunction or dialysis.
• * History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann's thrombasthenia or Bernard-Soulier syndrome.
• * History of hemophilia or bleeding disorders.
• * Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity.
• * Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.
• * Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.